Real-world comparison of eculizumab and efgartigimod for generalized myasthenia gravis

Francesco Saccà, MD, PhD, University of Naples Federico II, Naples, Italy, discusses the results of his study comparing eculizumab (a complement inhibitor) with efgartigimod (an FcRn inhibitor) based on real world evidence. Both cohorts of patients had good improvement according to Myasthenia Gravis Activities of Daily Living Scale (MG-ADL), with no significant difference seen. However, when looking at Quantitative Myasthenia Gravis (QMG) scores, considered to be the most objective measure of MG, patients treated with eculizumab had a significantly better response. Eculizumab also showed better results in terms of in prednisone-sparing activity, and frequency of MG deteriorations, MG crisis, and need for rescue medications. Treatment retention was also higher on eculizumab. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.